Rees Cattermole Psychologist - Exercise & Sports Medicare: Not Enrolled in Medicare Practice Location: 10218 Bay Ave, Englewood, FL 34224 Phone: 941-830-1546 |
Robert W Lees, M.A. Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 8591 Lakeside Dr, Englewood, FL 34224 Phone: 855-832-6727 Fax: 772-675-9100 |
Joseph J Amato, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1004 Topelis Dr, Englewood, FL 34223 Phone: 203-554-3420 |
Lynn R Bernstein, PH.D Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1861 Placida Rd Ste 101, Englewood, FL 34223 Phone: 941-474-7170 Fax: 941-475-2955 |
Paul C Powers Psychologist Medicare: Not Enrolled in Medicare Practice Location: 218 Brandywine Cir, Englewood, FL 34223 Phone: 941-681-2304 |
News Archive
Radioactive iodine may be selectively used for the treatment of intermediate-risk papillary thyroid cancer in patients who are aged over 45 years with tumors smaller than 4 cm that are confined to the thyroid gland, say US scientists.
A new study published ahead of print in the Clinical Chemistry and Laboratory Medicine (CCLM) journal reports the production of a robust immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the Pfizer-BioNTech BNT162b2 vaccine. The increase in humoral immunity includes elevated Immunoglobulin G (IgG) and Immunoglobulin A (IgA) levels after the second mRNA dose.
Pennsylvania's first probable human case of West Nile Virus (WNV) infection in 2014 has been detected. A Philadelphia County man was hospitalized due to WNV. He has since recovered.
Vaccination may be the most effective public health intervention of all time-especially in low-income countries, where many families can't access or afford health care when they are sick. On Friday, January 29, speaking at the World Economic Forum in Davos, Switzerland, Bill and Melinda Gates announced a new ten-year Gates Foundation commitment to funding vaccine development and delivery.
Compugen Ltd. announced today that it has signed a research collaboration agreement with Seattle Genetics, Inc., USA, covering a Compugen-discovered oncology target. The agreement provides Seattle Genetics with an initial evaluation period and an option for an exclusive worldwide milestone and royalty bearing license for development and commercialization of monoclonal antibody therapeutics addressing this novel target.
› Verified 8 days ago